Fig. 5

The CPT1A inhibitors entering clinical trials and their targets. Acaa1a acetyl-CoA acyltransferase, ACOX1 acyl-CoA oxidase 1, ADH1 alcohol dehydrogenase 1, AP1S1 adaptor related protein complex 1 subunit sigma 1, ASAH1 N-acylsphingosine amidohydrolase 1, ASNS asparagine synthetase, ATF4 activating transcription factor 4, CLU clusterin, COX4I1 matrix cytochrome C oxidase subunit 4I1, CRAT carnitine acetyltransferase, DEPP1 DEPP autophagy regulator 1, EHHADH enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase, EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1, FABP1 fatty acid binding protein 1, FNDC4 fibronectin type III domain containing 4, GDPD3 glycerophosphodiester phosphodiesterase domain containing 3, G6PD glucose-6-phosphate dehydrogenase, HPN hepsin, HPX hemopexin, INHBE inhibin subunit beta E, KCNH2 potassium voltage-gated channel subfamily H member 2, LSS lanosterol synthase, MT1A metallothionein 1A, NROB2 nuclear receptor subfamily 0 group B member 2, NUPR1 nuclear protein 1, transcriptional regulator, PRKCB protein kinase C beta, RPS9 ribosomal protein S9, SERCA2 sarco-endoplasmic reticulum calcium ATPase 2, SERPINA3 serpin family A member 3, SLC10A1 solute carrier family 10 member 1, TAGLN transgelin, TMPRSS2 transmembrane serine protease 2, TP53 tumor protein p53, UCP2 uncoupling protein 2, WIPI1 WD repeat domain, phosphoinositide interacting 1, T2DM type 2 diabetes mellitus